Edgestream Partners L.P. Boosts Holdings in Danaher Co. (NYSE:DHR)

Edgestream Partners L.P. grew its holdings in shares of Danaher Co. (NYSE:DHR) by 466.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,965 shares of the conglomerate’s stock after acquiring an additional 9,028 shares during the quarter. Edgestream Partners L.P.’s holdings in Danaher were worth $3,048,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in DHR. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher in the second quarter worth approximately $25,000. nVerses Capital LLC bought a new position in shares of Danaher in the second quarter worth approximately $25,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Danaher in the third quarter worth approximately $39,000. MidAtlantic Capital Management Inc. bought a new position in shares of Danaher in the third quarter worth approximately $40,000. Finally, MFA Wealth Advisors LLC bought a new position in shares of Danaher in the second quarter worth approximately $51,000. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR opened at $239.69 on Monday. The stock has a 50-day moving average price of $254.59 and a 200-day moving average price of $259.41. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm has a market cap of $173.12 billion, a PE ratio of 45.74, a P/E/G ratio of 4.41 and a beta of 0.85. Danaher Co. has a 1 year low of $215.68 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. Danaher’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.02 EPS. Sell-side analysts predict that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is 20.61%.

Analysts Set New Price Targets

DHR has been the topic of several recent analyst reports. Stifel Nicolaus raised their target price on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a report on Thursday, October 31st. KeyCorp lifted their price target on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. StockNews.com upgraded shares of Danaher from a “hold” rating to a “buy” rating in a report on Wednesday, November 27th. Finally, UBS Group cut their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.